The United Kingdom and the United States have concluded a important bilateral deal that will keep no duties on British pharmaceutical shipments being sold in the US market.
The Terms of the Accord
As part of the deal, the UK has pledged to raise spending on medicines through the National Health Service (NHS). This pledge ensures that tariffs on these crucial products will stay at nothing for a period of the next three years.
This development follows earlier warnings to dramatically increase duties on patented drug imports, with figures discussed reaching 100%.
"This arrangement with the UK reinforces the worldwide climate for innovative medicines and brings much-needed fairness to transatlantic medicine commerce," a release said.
Trade Importance
Pharmaceuticals represent one of the the United Kingdom's most significant export categories to the US, which is clearly the primary destination for large British pharmaceutical firms.
Statistics reveal that in the year prior to September, the UK exported drugs worth £11.1bn to the US. This figure accounted for a significant portion of all goods exports in that timeframe.
"This deal secures work, stimulates funding and facilitates the UK to emerge as a global hub for life sciences," a minister stated.
Specific UK Commitments
The pact involves several notable pledges from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must return to the NHS to prevent overspending will be capped at fifteen percent. Previously, repayments were more than twenty percent.
Industry Background
The deal takes place against a protracted row between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
The disagreement were heightened by assertions that US customers were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or abandoned, while major funding commitments have been directed toward projects in the United States.
One official acknowledged that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the past decade.
